Non-profit drug developer, TB Alliance has granted global
pharma major Lupin, a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug BPaL regimen. Lupin intends to commercialize the antituberculosis (TB) medicine in approximately 140 countries and territories, including many of the highest TB burden countries around the world.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
